Israel - Tiếng Do Thái - Ministry of Health

אניטה - מחדש ומחזק מראה השיער

Israel - Tiếng Do Thái - Ministry of Health

אניטה - מחדש מראה השיער

Israel - Tiếng Do Thái - Ministry of Health

אלסנדרו בעמ - חיזוק הציפורניים

Israel - Tiếng Do Thái - Ministry of Health

biotis ltd - terazosin as monohydrachloride dihydrate - טבליה - terazosin as monohydrachloride dihydrate 5 mg - terazosin - terazosin - for symptomatic treatment of urinary obstruction caused by benign prostatic hypertrophy (bph). for mild to moderate hypertension.

Israel - Tiếng Do Thái - Ministry of Health

biotis ltd - terazosin as monohydrachloride dihydrate - טבליה - terazosin as monohydrachloride dihydrate 10 mg - terazosin - terazosin - for symptomatic treatment of urinary obstruction caused by benign prostatic hypertrophy (bph). for mild to moderate hypertension.

Israel - Tiếng Do Thái - Ministry of Health

biotis ltd - erythromycin - אבקה להכנת תמיסה לאינפוזיה - erythromycin 1 g/vial - erythromycin - erythromycin - for the treatment of bacterial infections susceptible to erythromycin and require i.v. treatment .

Israel - Tiếng Do Thái - Ministry of Health

biotis ltd. - כלל האוכלוסיה - "קרם,קצף ותמיסה לאקזמה"

Israel - Tiếng Do Thái - Ministry of Health

biotis ltd. - כלל האוכלוסיה - תרסיס למניעת נחירות

Israel - Tiếng Do Thái - Ministry of Health

biotis ltd. - כלל האוכלוסיה - ג'ל להקלה על גירויים בפי הטבעת

Israel - Tiếng Do Thái - Ministry of Health

medison pharma ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 30 mcg / 0.5 ml - interferon beta-1a - interferon beta-1a - treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.